In a significant step forward for veterans' healthcare, SoftWave Tissue Regeneration Technologies (SoftWave TRT) has been awarded a Federal Supply Schedule Contract by the Department of Veterans Affairs. Effective from July 15, 2023, to July 14, 2028, the contract—numbered 36F79723D01671—falls under Schedule 65 II A, dedicated to Medical Equipment and Supplies as part of Federal Supply Schedule...Read More
At the May meeting, the Current Procedural Terminology (CPT) Editorial Panel approved the reimbursement code X170T that was developed and submitted by SoftWave for Low Intensity Extracorporeal Shock Wave Therapy (Li-ESWT). Kennesaw, GA, May, 4– In March 2022, Chris Holt joined SoftWave TRT as a strategic advisor and co-CEO, bolstering the company's growth and clinical...Read More
SoftWave officially has been granted 4 new patents as of July 19, 200. They include e U.S. Patient No. 11,389,373 B2 for Acoustic shock wave therapeutic methods to prevent or treat opioid addiction, U.S. Patient No. 11,389,370 B2 for Treatments for blood sugar levels and muscle tissue optimization, U.S. Patient No. 11,389,371 B2 and U.S....Read More
SoftWave® Tissue Regeneration Technologies, a disruptive bio-medical device company, announces the beginning of a trial for “Extracorporeal Shock Wave Therapy in Acute Traumatic Complete and Incomplete Cross – Sectional Lesions.” The trial will be sponsored by the Austrian Workers’ Compensation Board (AUVA). It will be conducted in 13 hospitals in Austria and one in Germany,...Read More
ATLANTA, May 19, 2021 (Newswire) – SoftWave Tissue Regeneration Technologies patented extracorporeal shock wave device called the OrthGold 100® was cleared by the FDA on May 4, 2021, for the indications of a temporary increase in local blood circulation, relief of minor aches and pains, and activation of connective tissue. (FDA 510(k) letter-number K210451.) According to...Read More
